These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27721530)

  • 21. The role of mouse tumour models in the discovery and development of anticancer drugs.
    Ireson CR; Alavijeh MS; Palmer AM; Fowler ER; Jones HJ
    Br J Cancer; 2019 Jul; 121(2):101-108. PubMed ID: 31231121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.
    Wartha K; Herting F; Hasmann M
    Pharmacol Ther; 2014 Jun; 142(3):351-61. PubMed ID: 24412280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
    Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
    Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs.
    Drell TL; Zanker KS; Entschladen F
    Curr Pharm Des; 2012; 18(23):3416-20. PubMed ID: 22663553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein.
    Qi X; Chu Z; Mahller YY; Stringer KF; Witte DP; Cripe TP
    Clin Cancer Res; 2009 Sep; 15(18):5840-51. PubMed ID: 19737950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
    De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
    Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer.
    Decaudin D
    Anticancer Drugs; 2011 Oct; 22(9):827-41. PubMed ID: 21623183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical phase II studies in human tumor lines: a European multicenter study.
    Boven E; Winograd B; Fodstad O; Lobbezoo MW; Pinedo HM
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):567-73. PubMed ID: 3383962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiologically relevant in vitro tumor models for drug screening.
    Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
    Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
    Growcott JW
    Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical development of molecular-targeted agents for cancer.
    Ocana A; Pandiella A; Siu LL; Tannock IF
    Nat Rev Clin Oncol; 2010 Dec; 8(4):200-9. PubMed ID: 21135887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
    LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
    Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.